BIIB059 is a monoclonal antibody that blocks BDCA2, which inhibits the production of inflammatory mediators in SLE. A Phase 1 trial showed drug to be safe& tolerable. It continues being investigated in SLE& cutaneous #lupus. #EULAR2019 #InsideLupusResearch https://t.co/bbcV3W57DD
Links:
EULAR Abstract Archive
https://cards.twitter.com/cards/cc2nz/7jsac
Jun-15-2019
